Literature DB >> 26346210

Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings.

Megan Corrigan1, Suprat Saely Wilson1, Jeremy Hampton2.   

Abstract

PURPOSE: The safety and efficacy of medications that may be administered via the intranasal route in adult patients in the prehospital and emergency department (ED) settings are reviewed.
SUMMARY: When medications of appropriate molecular character and concentration are delivered intranasally, they are quickly transported across this capillary network and delivered to the systemic circulation, thereby avoiding the absorption-limiting effects of first-pass metabolism. Therapeutic drug concentrations are rapidly attained in the cerebrospinal fluid, making intranasal administration a very effective mode of delivery. To optimize the bioavailability of intranasally administered drugs, providers must minimize the barriers to absorption, minimize the volume by maximizing the concentration, maximize the absorptive surface of the nasal mucosa, and use a delivery system that maximizes drug dispersion and minimizes drug runoff. Medications can be instilled into the nasal cavity with syringes or droppers by applying a few drops at a time or via atomization. The intranasal route of administration may be advantageous for patients who require analgesia, sedation, anxiolysis, termination of seizures, hypoglycemia management, narcotic reversal, and benzodiazepine reversal in the ED or prehospital settings. Medications that have been studied in the adult population include fentanyl, sufentanil, hydromorphone, ketamine, midazolam, haloperidol, naloxone, flumazenil, and glucagon. The available data do indicate, however, that intranasal administration may be a safe, effective, and well tolerated route of administration.
CONCLUSION: Based on the published literature, intranasal administration of fentanyl, sufentanil, ketamine, hydromorphone, midazolam, haloperidol, naloxone, glucagon, and, in limited cases, flumazenil may be a safe, effective, and well-tolerated alternative to intramuscular or intravenous administration in the prehospital and ED settings.
Copyright © 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26346210     DOI: 10.2146/ajhp140630

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  13 in total

Review 1.  Imaging of intranasal drug delivery to the brain.

Authors:  Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-02-25

2.  Maximum volume of nasal administration using a mucosal atomization device without aspiration in Japanese White rabbits.

Authors:  Yixian Wei; Ai Hori; I-Ying Chen; Haruka Tamogi; Taku Hirokawa; Keiko Kato; Takaharu Itami; Tadashi Sano; Kazuto Yamashita
Journal:  J Vet Med Sci       Date:  2022-04-11       Impact factor: 1.105

3.  Quality of analgesia in physician-operated telemedical prehospital emergency care is comparable to physician-based prehospital care - a retrospective longitudinal study.

Authors:  Niklas Lenssen; Andreas Krockauer; Stefan K Beckers; Rolf Rossaint; Frederik Hirsch; Jörg C Brokmann; Sebastian Bergrath
Journal:  Sci Rep       Date:  2017-05-08       Impact factor: 4.379

4.  Intranasal epinephrine in dogs: Pharmacokinetic and heart rate effects.

Authors:  Kenneth L Dretchen; Zack Mesa; Matthew Robben; Desmond Slade; Scott Hill; Claire Croutch; Kyle Kappeler; Michael Mesa
Journal:  Pharmacol Res Perspect       Date:  2020-04

Review 5.  Pre-hospital pain management; a systematic review of proposed guidelines.

Authors:  Mahmoud Yousefifard; Shaghayegh Askarian-Amiri; Arian Madani Neishaboori; Mostafa Sadeghi; Peyman Saberian; Alireza Baratloo
Journal:  Arch Acad Emerg Med       Date:  2019-10-06

6.  Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study.

Authors:  Lara Kay; Nina Merkel; Anemone von Blomberg; Laurent M Willems; Sebastian Bauer; Philipp S Reif; Susanne Schubert-Bast; Felix Rosenow; Adam Strzelczyk
Journal:  Ann Clin Transl Neurol       Date:  2019-11-04       Impact factor: 4.511

Review 7.  Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic.

Authors:  Jenny K W Lam; Chucky C K Cheung; Michael Y T Chow; Emily Harrop; Susie Lapwood; Stephen I G Barclay; Ian C K Wong
Journal:  Adv Drug Deliv Rev       Date:  2020-11-01       Impact factor: 15.470

Review 8.  Advances in intranasal application of stem cells in the treatment of central nervous system diseases.

Authors:  Yu-Ting Zhang; Kai-Jie He; Jin-Bao Zhang; Quan-Hong Ma; Fen Wang; Chun-Feng Liu
Journal:  Stem Cell Res Ther       Date:  2021-03-24       Impact factor: 6.832

9.  Use of peripheral vascular access in the prehospital setting: is there room for improvement?

Authors:  Erin Gonvers; Thierry Spichiger; Eric Albrecht; Fabrice Dami
Journal:  BMC Emerg Med       Date:  2020-06-09

Review 10.  A Review of Malaysian Herbal Plants and Their Active Constituents with Potential Therapeutic Applications in Sepsis.

Authors:  Kong Yen Liew; Md Faizul Hafiz; Yi Joong Chong; Hanis Hazeera Harith; Daud Ahmad Israf; Chau Ling Tham
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.